Key Takeaways
- NTLA shares climbed 25% on pre-announcement momentum but retreated 3% following the actual data release
- The Phase 3 HAELO study achieved its primary goal along with every significant secondary objective
- One administration of lonvo-z delivered an 87% decrease in hereditary angioedema episodes compared to control
- The company has initiated a rolling biologics license application with the FDA
- If regulatory approval is granted, U.S. commercial availability could begin in early 2027
Shares of Intellia Therapeutics experienced dramatic volatility throughout Monday’s trading session. The stock rocketed 25% higher as market participants anticipated the Phase 3 data announcement, only to surrender those advances and finish the day down 3% after the findings became public.
Intellia Therapeutics, Inc., NTLA
The clinical data, however, proved impressive. The HAELO study evaluating lonvoguran ziclumeran—abbreviated as lonvo-z—successfully achieved both its primary goal and all critical secondary measures.
Participants receiving the experimental treatment experienced an 87% reduction in hereditary angioedema attacks relative to those on placebo. The average monthly attack frequency registered at just 0.26 for treated patients versus 2.10 among the control cohort.
Eighty individuals participated in the study. Fifty-two were administered lonvo-z, while 28 received placebo. The majority of treated subjects remained attack-free and did not require additional ongoing therapy during the six-month assessment period.
Based on data captured through February 10, every patient who received lonvo-z maintained freedom from long-term preventive treatment. This represents an encouraging outcome for what’s designed as a single-administration therapy.
The treatment’s safety characteristics also proved favorable. The most frequently observed side effects included infusion-related reactions, headache, and fatigue. All documented adverse events were classified as mild to moderate severity—zero serious adverse events occurred among lonvo-z recipients.
Regulatory Path Forward
Intellia has commenced a rolling submission of its biologics license application to the FDA. Should the agency grant approval, the organization aims to introduce the therapy to the U.S. market during the first half of 2027.
The treatment mechanism involves deactivating the KLKB1 gene to achieve sustained reduction of kallikrein and bradykinin concentrations. Administration occurs via a single infusion in an outpatient clinical setting.
This achievement also marks a pivotal advancement for gene editing technology. The HAELO trial delivers the first worldwide Phase 3 clinical readout for an in vivo gene editing therapeutic approach.
Additional findings from the study will be shared at the 2026 European Academy of Allergy and Clinical Immunology Congress scheduled for June.
Financial Metrics for NTLA
Intellia maintains a market capitalization of approximately $1.61 billion. The company’s GF Score registers at 70 out of 100, featuring a Growth Rank of 7/10 while posting a Profitability Rank of merely 1/10.
The price-to-sales ratio stands at 21.93, indicating market expectations centered on substantial future expansion rather than present-day profitability.
Insider transaction activity has remained minimal. No share purchases occurred during the previous three months, though two selling transactions involving 1,818 units were documented.
The organization maintains strategic partnerships with Regeneron and Novartis to advance its expanded development pipeline, which encompasses potential treatments for ATTR amyloidosis and sickle cell disease.
Further clinical findings from HAELO are scheduled for presentation at the EAACI Congress in June 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
